Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Memantine: Phase IIb

NTII presented additional data from its previously reported 421-patient U.S. Phase IIb

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE